Whether Ono Pharmaceutical Korea’s ‘Opdivo Inj’ will receive reimbursement as the first first-line immunotherapy option for gastric cancer is gaining attention.

If the drug is reimbursed as a first-line treatment for gastric cancer, Opdivo Inj may closely chase the sales of Keytruda, which had expanded coverage as a first-line treatment for non-small cell lung cancer in the immuno-oncology drug market.

Three doses of Opdivo Inj were included in the updated list of drugs for which drug price negotiations were recently completed by the National Health Insurance Service. The list contains all the drugs that have completed pricing negotiations by the 10th of this month.

Afte